William Stilley: Working On New Alcohol Addiction Treatments At Adial Pharmaceuticals

William Stilley: Working On New Alcohol Addiction Treatments At Adial Pharmaceuticals

Imagine a world where addiction treatments are tailored to your unique genetic makeup. In this episode of 'The Rehab', William Stilley, the CEO and founder of Adial Pharmaceuticals, takes us on a journey through their groundbreaking work in alcohol addiction treatment. Unlike many pharmaceutical companies that rely on broad-spectrum drugs, Adial is crafting new molecules designed to precisely target specific receptors in the brain.

This approach aims to minimize side effects and enhance treatment effectiveness, especially for those with a particular genetic profile. Stilley breaks down the science in simple terms, making complex concepts accessible to everyone. He shares how their innovative drug, currently in phase three trials, could become the first genetically targeted therapy for alcohol use disorder available to the public.

The conversation doesn't stop there; Stilley also touches on another promising drug in development aimed at pain relief, which works by boosting adenosine levels without the negative effects associated with caffeine. For anyone interested in the future of addiction treatment and the potential of personalized medicine, this episode offers a fascinating glimpse into what's possible. Tune in to discover how Adial Pharmaceuticals is leading the charge in revolutionizing addiction recovery.